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Abstract 
The TNF initiated processes are simulated using our integrative computational model 
with new quantitative proteomics data obtained on HeLa cell line. In spite of fact, that 
the model development is based on limited experimental information, with missing 
data estimated by simulations and parametrization using indirect experiments on 
different cell lines, the actual model with HeLa experimental data provides pleasant 
agreement between the computationally predicted behavior and experiments. Since no 
significant departures from experimentally determined functionality of HeLa cells has 
been observed, this can be taken as encouraging sign, that substantial features of the 
cell line behavior are reproduced correctly and indicate new possibilities for cell-line 
specific computational experiments. 
Keywords: HeLa cells, quantitative proteomics, TNF apoptotic pathway, systems 
biology model 
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Introduction 
Reaction kinetic models of systems biology form important tools in our effort to 
understand complex biological processes at molecular level. In recent decade, hundreds 
of such models were reported, covering growing parts of various biological processes 
and their regulation. Being integrative, these models are seldom created from scratch, 
they are gradually build and refined to cover widening range of molecules, interactions 
and phenomena, accommodating new knowledge as it arrives. Formally exact and 
quantitative, such models comprise big part of our knowledge about processes, 
specified in terms of time course of populations of individual molecular species. The 
attractiveness of this approach stems from the mathematical rigorosity, allowing 
formulation of very compact, computer readable and processable, internally coherent 
framework. Quantitative models created within the framework allow numerical 
simulations of the modeled system behavior, even for processes and phenomena of 
considerable complexity. There is now established common model description 
language SBML (Hucka et al., 2003), as well as the repositories of models (Li et al., 
2010), (Lloyd et al., 2004) facilitating the developments, sharing and use of such 
models. Due to the quantitative character of the reaction kinetic models, their 
construction and utilization requires considerable amount of quantitative information. 
Since the availability of experimental data is limited and available data are sometimes 
contradictory, the generality of the model and its plausibility in different context is not 
automatically guaranteed. Even for well researched topics, with thousands of 
experimental papers published each year, such as apoptosis, available experimental 
data cannot provide full, unambiguous and direct information, required by such 
models. In practice, many compromises are to be made in such model constructions, 
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starting from the model reaction and interactor setup, through parametrization of 
reaction rates and concentrations. Lack of generally available reliable quantitative data 
makes model construction slow and iterative work, where new experimental data or the 
application of the model on new subject (organism or cell line) generally requires 
adjustment and often re-parametrization of the model. 
Apoptosis - most known form of programmed cell death - is studied for more than 
century. The errors in apoptosis regulation are amongst the principal causes of tumoral 
and autoimmune diseases. The understanding of the regulation of apoptotic signaling 
pathways and the discovery of treatment-sensitive mechanisms is seen by many as the 
way toward the design of more effective and target-selective therapeutic strategies 
(Spencer and Sorger, 2011). 
Apoptosis may be induced due to changes in internal cell state or due to external stimuli 
originating from the cell exterior. Intrinsic stimuli capable of initiating apoptosis 
include stress, UV radiation, ionizing radiation, activation of oncogenes, exposition to 
toxins etc. All these stimuli cause permanent cellular damage or significant 
deterioration of cell functioning, recognized inside the cell and provoking cell death 
response. Extrinsic apoptosis is triggered by extracellular death ligands bound to 
specific trans-membrane cell death receptors of the Tumor Necrosis Factor Receptor 
(TNFR) family (Gonzalvez and Ashkenazi, 2010) and activating signaling pathways 
dependent on caspases. Both intrinsic and extrinsic pathways to apoptosis share 
significant amount of common components and regulatory mechanisms. Due to 
extensive cross-talks, the comprehensive model of extrinsic apoptotic processes must 
thus incorporate also significant portions of the intrinsic pathways. 
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The regulation of apoptosis is crucial for the correct functionality of multicellular 
organisms, and as such must be tightly controlled. The general mechanism of apoptosis 
regulation must be adaptable, to provide cell-line and cell-state specific responses for 
the same signal. Obviously, this requires robust, reliable and tunable mechanism, where 
quantitative differences on input translate into qualitatively different outcomes. 
Apparently, in order to understand the behavior of apoptotic machinery, the qualitative 
description of the mechanism should be accompanied by the quantitative treatment. 
Due to complexity of such models, predictions usually cannot be made analytically, 
relying instead on numerical simulations. 
It is thus of significant importance to be able to test the usability of the quantitative 
models in situations, where new experimental data appear, unknown at the time of 
model construction. 
Very recently, quantitative proteomics data were published for human U2OS (Beck et 
al., 2011) and HeLa cell lines (Nagaraj et al., 2011). This independent experimental set 
can be used for the critical evaluation of the functionality of computational models, 
created without this information. The computational models of systems biology work 
with absolute quantities of the molecules and their time evolution. This information is 
not readily available, since most experimental data are relative, reporting only 
proportions between the species and the measurements are indirect, relying on 
experimental estimations of intermediates and proxies, with interpretation based on 
model assumptions. As a result, experimental data used in computational model are 
vulnerable to sample preparation and interpretation artifacts. Experimental protocols 
allow usually to trace only few of the parameters of interest, while the integrative 
models work with much bigger sets. The quantitative proteome represents the most 
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direct estimations of the quantities appearing in models - the counts of interacting 
molecules in their reaction volumes. The appearance of quantitative proteomics 
measurements for the complex human cell lines allows, for the first time, to address 
systematically the question of model sufficiency and its predictive power. 
Comprehensive quantitative experimental data obtained on the single cell line under 
consistent experimental conditions provide opportunity to take a fresh look at known 
predictive models of apoptotic processes initiated through TNF (Koh and Lee, 2011), 
(Schliemann et al., 2011) when integrated into a single model (Fig. 1.). 
The combination of new comprehensive data and their use together with our 
quantitative model provides interesting test of the quality and applicability of the model 
and the positive results provide solid ground for further modeling work as they 
encourage to explore other experimental sources of less reliable nature (such as 
micro-array data) and extrapolate those data in new, adapted models with higher 
confidence. 
Material and methods 
The construction of the quantitative model is formidable task, seldom created from 
scratch. There is clear evolution of the models, where the subsequent models often 
build on previous work of other authors, taking substantial part of the reaction networks 
and sharing collected quantitative data, such as reaction rates and concentrations. The 
construction of our model is no exception. Recently published model of TNF 
signalization by Schliemann et al. (Schliemann et al., 2011) provided core interaction 
patterns to our integrative model of apoptosis, describing the death receptors part. The 
interactions of the model of Schliemann et al. described the formation of signaling 
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complex I and II, the internalization of the complexes into cytosol, proliferatory and 
apoptotic blocks as well as comparatively detailed activation of caspase–8 and 
p43-FLIP fragment. Their study was based specifically on KYM1 cells, so the 
application of the model to more general treatment is not automatic. The sensitivity of 
KYM1 cell line (derived from human rhabdomyosarcoma) to TNF stimulus is not 
affected by excessive production of Bcl–2 or Bcl-xL proteins (Grell et al., 1999). 
KYM1 are cells of type I, i.e. the activated apoptosis pathways are not dependent on 
mitochondria, and as such, the intrinsic pathway part of the model is missing in this 
model. KYM1 cells are highly responsive to TNF stimuli, even in the absence of 
metabolic inhibitors, including the inhibitors of DNA synthesis (Grell et al., 1994), 
allowing for rapid development of apoptosis. 
In order to provide more comprehensive model of TNF initiated apoptosis, we have 
made several modifications and extensions, documented below. The model of 
Schliemann et al. was complemented by mitochondria-specific part, where the structure 
of interactions and parametrization follows closely the seminal paper of Albeck et al. 
(Albeck et al., 2008b) recently actuated by explicit models of protein synthesis and 
degradation as described by Spencer (Spencer et al., 2009) and Aldridge (Aldridge et 
al., 2011). 
Model construction 
The resulting mathematical model contains 84 molecules (including the intermediate 
forms) and 156 reactions, including those describing the synthesis of mRNA and 
translation of selected proteins, transport processes between the mitochondria, 
cytoplasm and nuclei, as well as de novo synthesis and degradation of proteins. The 
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schematic of the model, comprising most important functional blocs, is depicted on 
Fig.1. For clarity, some intermediates, protein synthesis and degradation reactions are 
not plotted. All reactions are of mass action kinetics type. The molecular interaction 
network, in terms of nodes and topology is specified in Table 1. 
The initial concentrations of species used in the model are taken from the experimental 
proteomics data (Nagaraj et al., 2011). The use of this data is based on assumption that 
the HeLa cells are in the survival steady state, i.e. without executing the apoptotic 
program. Mitochondria are intact and the molecules are not modified by excessive 
phosphorylation or cleaved. This is reflected by the numerical values for 
phoshorylated, cleaved molecules and majority of intermediate products set to zero. 
The mass spectrometry (MS) data contain no information about the FLIP and BAR 
molecules. Since FLIP and BAR play important role in previous models of apoptosis  
(Albeck et al., 2008b) (Spencer et al., 2009), this point requires some discussion. Here 
we expect the low concentrations, too low to be detected reliably by MS and reported in 
the data set. This corroborates the assumption that the cell culture was in the 
pro-survival state. The stimulation by TNF is known to cause rapid synthesis of FLIP 
due to NFkB activation. Another critical component, the TNFR1 receptor, is also 
missing in the MS data. For TNFR1 this points to known deficiency of MS for 
membrane-bound proteins, as commented in the original experimental MS paper. It is 
generally known (Jupp et al., 2001) that HeLa cells contain about 3000 TNFR1 
receptors on cell surface. The production rates of newly synthesized TNFR1 in cytosol 
was set to balance the rate of externalization and degradation of the externalized 
receptor, adopted from Schliemann et al., in order to keep the number of receptors for 
HeLa external membrane at this value. 
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Compartment size estimation 
Since source models specify amounts of species in concentrations, rather than the 
preferable absolute counts of molecules (numerical concentrations), the integration of 
simulation data from other models into our model requires to make assumptions about 
the reaction volumes. The reported size of HeLa cells is between 1200 to 4290 m3 
(Zhao et al., 2008). For our simulations, we have used an average volume of 2425 m3. 
The volume of nucleus 375 (Maul and Deaven, 1977) to 690 m3 (Monier et al., 2000) 
corresponds to 15–28 % of the total cell volume. In our simulations, we have opted for 
the reference volume of nucleus at the 25% of the total cell volume. The typical volume 
of mammal cell mitochondria is 0.5 m3 (Mitochondria volume - Mammalian tissue 
culture cell - BNID 100438). The number of mitochondria in the cell varies, depending 
on the actual phase of cell cycle. In early phase of G1 cycle, is the number of 
mitochondria in HeLa about 400, later, in S and G2 phase it rises to 500–600 (Posakony 
et al., 1977). Only 5% of the HeLa population is in mitosis, 95% are thus in the 
interphase (G1+G2+S). Since in the interphase the cell in the state G1 spends roughly 
the same time as in the states G2+S, we have utilized the average number of 
mitochondria 500. This corresponds to the volume of mitochondria in the range 
200–300 m3 (8–12% of the total cell volume). In further simulations, we have set the 
reference volume of mitochondria to 10% of the total cell volume. 
Estimation of reaction rates 
Whenever available, kinetic reaction parameters were transferred from the existing 
partial models (Schliemann et al., 2011), (Albeck et al., 2008b), (Spencer et al., 2009), 
(Aldridge et al., 2011) and converted to the same units (suitable for simulations using 
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numerical concentrations) and for reference volumes. Resulting reaction rates, obtained 
by reaction speeds for individual compartments were normalized to the compartment 
volumes (the volume of nuclei and the total volume of mitochondria) relative to the 
total volume of cytosol, according to methodology of Albeck (Albeck et al., 2008b). 
Thus obtained reaction rates are summarized in the Tables 2 and Table 3. 
Initial concentrations 
Protein concentrations were taken unmodified, from the comprehensive quantitative 
proteomics data published recently by Nagaraj et al. (Nagaraj et al., 2011) for the HeLa 
cells. The size of the stimulus and the actual amount of mRNA were considered as 
independent variables driving the model. The mRNA amounts for selected proteins 
were used those of Schliemann et al. (Schliemann et al., 2011) without modification. 
Although the data are obtained for KYM1 cell line, numerical simulations showed, that  
the initial amount of mRNA varied over one order of magnitude up or down had only 
marginal effect on the onset of apoptosis. The quantitative proteomics data provide 
only the total number of NFkB and IkBa molecules, the information of the partitioning 
of these molecules into complexes and intermediates must be determined by other 
means. The values for NFkB, NFkB_N, IkBa, IkBa_N, IkBa:NFkB  and  IκBα:NFkB_N 
complexes were set to respect the experimental finding, that 9% of the total NFkB and 
17% of the IkBa is present at nuclei without TNF stimulation (Birbach et al., 2002) and 
taking into account that proteomics data report concentration of monomeric units, while 
the NFkB used in simulations is dimer. The same considerations were applied for the 
IKK protein, being a trimer. When protein is composed from several components 
reported as standalone units in MS data, the amount was estimated according to the 
most deficient compound. E.g. for IKK, composed of IKK1 (3500 molecules per cell 
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(#/cell)), IKK2 (6800 #/cell) and NEMO (34000 #/cell), the amount of IKK was set to 
3500 copies per cell. The numerical concentrations are listed in Table 3. 
The component models and functional blocks were numerically simulated and partial 
model results compared with the original simulation data to detect eventual misprints 
and omissions. All simulations were performed using Copasi (Hoops et al., 2006) 
framework and continuous deterministic time propagation algorithm (LSODA). During 
the simulations no critical volumes and concentrations were encountered requiring the 
more rigorous, though time consuming stochastic kinetics approach. The complete 
model is available in the Copasi format, which forms a superset of the SBML standard. 
Results 
Thus constructed model provides complex simulation environment capable of 
providing numerous computational experiments. In the result section we will describe 
few of the relevant characteristics of the model fed with experimental HeLa cells 
parameters, together with the references to the corresponding experimental behavior. 
Most attention will be payed to the sequence of events initiated after the stationary cell 
is exposed to proapoptotic signal TNF ligand. In the present paper, we focused on 
permanent stimulation, i.e. the situation, where the fixed number of TNF ligand is 
placed into cell exterior and then this number is decreased only due to internalization of 
the receptor complex. 
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The creation of signaling complex I 
TNF binding to the receptor TNFR1 leads to rapid formation of the transmembrane 
signaling complex I. Allosteric changes on the cytosolic side of receptor, induced by 
ligand, attract adaptor proteins TRADD, RIP1 and ubiquitin E3 ligase TRAF2. The 
presence of RIP1 protein is essential for the further propagation of the signal 
proceeding through binding and activation of IKK - following the proinflamatory and 
antiapoptotic NFkB signaling pathway. Activated IKK phosphorylates IkBa proteins in 
the complex IkBa:NFkB. Phosphorylated IkBa undergoes ubiquitination and 
subsequent degradation (by proteasome, in model only implicit), releasing thus NFkB. 
NFkB is then translocated into a nucleus, where it acts as a transcription factor, 
initiating the expression of many proinflamatory, antiapoptotic (XIAP, FLIP) and 
regulatory genes (represented in the model by A20). 
In actual HeLa simulations, the experimentally determined initial concentrations of 
adaptor proteins RIP1, TRADD, TRAF2 are low, compared to generic model 
assumptions (Table 4 ). This limits the speed of formation of both signaling complexes 
I and II and provides the upper limit for their absolute numbers. Compared to the state, 
when the cell contains sufficient number of adaptor proteins, the activation of NFkB 
pathway is delayed in time and of lower intensity (see Fig. 4. A, B). The formation of 
the signaling complex II, which activates the caspase–8 is slow. NFkB-independent 
synthesis of XIAP and FLIP, in later stages enhanced through NFkB activation, cause 
higher levels of XIAP and FLIP compared to the case when sufficient numbers of 
adaptor proteins are present. Thus, when adaptor protein levels are low, the activation 
of caspase–8 is delayed. 
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Internalization of the signaling complex I and 
the creation of signaling complex II 
The complex I is internalized (by clathrin-mediated endocytosis - details not modeled 
explicitly) within few minutes after the ligand binds TNFR1 receptor. NFkB 
signalization ceases to exist after ubiquitination and degradation of RIP1 and removal 
of TRAF2 from the complex I due to activity of ubiquitin-E3 ligases (Heyninck et al., 
1999), (Liao et al., 2008), (Zhao et al., 2008), (Chen, 2012). Signaling complex II is 
formed by mutual entrapment of FADD, TRADD, FLIP and procaspases–8 and –10, 
forming thus DISC complex associated with the receptor (Micheau and Tschopp, 
2003). The formation of DISC complex is detected already 3 minutes after the TNF 
stimulation and the complex remains associated with the receptor even after 60 minutes 
(Schütze and Schneider-Brachert, 2009). 
Activation of initiation caspases–8 and –10 
Instead of procaspases–8 and –10, catalytically inactive procaspase–8 homologue FLIP 
can bind to DISC. FLIP is has higher binding affinity than procaspase–8, though 
procaspase–8 is more abundant in cells (Neumann et al., 2010). Procaspase–8 interacts 
with procaspase–10 and FLIP, with FLIP being preferential interaction partner (Irmler 
et al., 1997), (Krueger et al., 2001), (Wang et al., 2001). FLIP is processed by 
caspase–8 to provide p43-FLIP, which binds and activates IkB kinase (IKK) (Lavrik et 
al., 2003). Activated IKK is known to phosphorylate and thus inhibit IkBa. IkBa 
downregulates NFkB, so the activation of IKK results in induction of NFkB-mediated 
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transcription (Scheidereit, 2006). Computer simulations and experiments indicate, that 
both signaling pathways (proapoptotic - caspase–8 dependent, as well as cell-survival - 
NFkB dependent) are activated concurrently and the final outcome is determined by the 
fine balance between the actual cellular levels of FLIP and initiator caspases. Neumann 
et al. (Neumann et al., 2010) showed the FLIP can switch off completely, induce or 
suppress the activation of NFkB, depending on whether the FLIP level is low, 
intermediate or high. The counterintuitive inhibition of NFkB for high levels of FLIP is 
due to inhibitory effect of high FLIP concentrations on production of p43-FLIP 
(Neumann et al., 2010). 
It has been documented that excessive concentration of FLIP limits the access of 
procaspase–10 to the procaspase–8 on DISC complex (Micheau and Tschopp, 2003). 
For cells with lower levels of FLIP, the lower affinity procaspase–10 associates with 
procaspase–8. This indicates, that the capturing of FLIP and procaspase–10 on 
signaling complex II are mutually exclusive, in other words they do not interact 
together. Procaspase–10 interacts only with procaspase–8 and itself, which points to 
completely different mechanism of activation compared to the caspase–8 (Micheau and 
Tschopp, 2003), (Feoktistova et al., 2011). 
Apoptosis type I or type II 
For extrinsic apoptotic pathway, two distinct mechanisms are described - type I and 
type II. Type II or automacrophagic cell death is attributed to cells with profound 
defects in apoptotic cell machinery (Tsujimoto and Shimizu, 2005). While more 
conventional apoptosis of type I doesn't require participation of mitochondria, in 
apoptosis type II extrinsic factors execute an apoptotic pathway with participation of 
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mitochondria, the significant part of which is shared with apoptosis induced by intrinsic 
factors. HeLa cells are representatives of the cell type II (Hippe et al., 2008), while the 
KYM1 cells exhibit conventional apoptosis type I (Schliemann et al., 2011). 
The key regulatory role in type I vs type II mechanism is played by the mutual ratio of 
XIAP vs. procaspase–3 (Aldridge et al., 2011). After the activation of the initiation 
caspases, apoptosis might proceed by non-mitochondrial pathway (cell type I) provided 
the ratio of XIAP/procaspase–3 is low. Initiation caspases for cell type I induce direct 
activation of the effector (executioner) caspases –3 and –7, with lethal outcome for the 
cell. Reinforcing positive feedback is formed through caspase–3 and –7 activating 
procaspase–6 and finally the activation of procaspase–8 (Albeck et al., 2008b). 
If, however, the ratio between the XIAP and procaspase–3 is high, there is too much 
XIAP in circulation, the activation of effector caspases–3 and –7 is suppressed by 
XIAP and the cell proceeds through permeabilization of the external mitochondrial 
membrane (MOMP). This behavior is defining the cell type II. The example of such 
behavior is illustrated on Fig. 2. Resulting effector caspases decompose structural 
proteins of the cell, such as cytokeratines and nuclear lamins, as well as inhibitors of 
caspase-activated DNAses (iCAD)and poly(ADP-ribose) polymerase (PARP) (Choi et 
al., 2009). Caspase activated DNAses (CAD) fragment the chromosomal DNA leading 
to easily observable DNA ladders - hallmarks of late stage apoptosis. The downstream 
processes after the activation of executioner caspases are not included in the model, 
though the beginning of this phase is manifested in our model as the cleavage of the 
PARP protein due to activity of caspase–3. 
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Mitochondrial apoptotic pathway 
During endocytosis the signaling complex II associates with trans-Golgi vesicules and 
forms with them multivesicular bodies (MVB). Active caspase–8 activates in MVB 
ceramid-cathepsin cascade, yielding Cathepsin D cleaving Bid protein to its truncated 
form tBid (Schütze and Schneider-Brachert, 2009). In the model, these processes are 
simulated through internalization of the receptor complex I, activation of caspase–8 and 
truncation of Bid into tBid. 
tBid activates Bax. Activated Bax translocates into external mitochondrial membrane 
where it oligomerizes (often with Bak) and forms permeable pores, through which 
mitochondria leak critical regulators of apoptosis, such as cytochrome-c and 
Smac/Diablo, normally localized in mitochondrial intermembrane space. 
The MOMP event is usually rapid process, lasting few minutes and it is considered to 
be the control point, after passing which the cell cannot recover from the apoptotic 
program  (point  of  no  return,  “all  or  nothing”  mechanism)  (Chipuk et al., 2006). The 
MOMP transition is clearly seen in the HeLa simulations with current parameters at 
about 9000 s from beginning (Fig. 2 and Fig.5). 
The MOMP transition is attributed to Bcl–2 apoptotic switch (Albeck et al., 2008b) and 
the transition is triggered when the levels of active Bax/Bak exceed the levels 
Bcl–2/Bcl-xL, which act as Bax/Bak inhibitors (Korsmeyer et al., 1993). The kinetics 
of rapid and complete translocation of Smac and cytochrome-c into cytosol through 
open pores is determined by large concentration gradients, where there is high 
concentration of these in intermembrane space of mitochondria, while initially 
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practically absent in cytosol (Spencer and Sorger, 2011). 
Cytochrome-c dislocated into cytosol forms - together with Apaf–1 and procaspase–9 - 
apoptosome. Apoptosome cleaves and activates effector procaspases. Available free 
XIAP associates with catalytic domain of active effector caspases–3 (and caspase–7 not 
included explicitly in the model), preventing their protease activity and promoting their 
ubiquitination and thus their degradation. Smac, bound to XIAP, allows to weaken this 
inhibition, so effector caspases can cleave their substrates and cause cell death (Chipuk 
et al., 2006). 
Discussion 
Single cell experiments using FRET showed, that before MOMP, the activity of 
effector caspases is negligible, while the initiation caspases are active even before 
MOMP and the products of their substrates Bid and procaspase–3 accumulate in their 
cleaved form (Albeck et al., 2008a) (Fig. 5). Caspase–3 is very efficient enzyme: 
computational simulations supported by experiments indicate, that 400 active 
molecules are sufficient to cleave 106–107 molecules of substrate in the course of 
several hours (Li et al., 2010). The delayed activation of effector caspases is attributed 
to two mechanisms: competitive XIAP binding to the catalytic site of caspase–3 (which 
is reversible process) and irreversible ubiquitination and degradation of caspase–3 
through E3 ligase XIAP (Albeck et al., 2008b). The time between the cells are exposed 
to TNF and  the  MOMP  thus  represents  perhaps  the  state  of  “latent  death”,  where  the  
effector procaspases are continuously activated, but at the same time their active forms 
are inhibited and the active caspases are effectively degraded through actions of XIAP. 
This steady-state situation lasts till the release of Smac during MOMP event (Spencer 
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and Sorger, 2011). Then, three possible scenaria might happen: low levels of XIAP 
allow the effector caspases to cleave the substrates completely, while abundant XIAP 
inhibits the effector caspases completely. For intermediate levels of XIAP, slow 
intermediate cleavage, proceeding at suboptimal speed, might appear, leading to 
genomic instability (Lovric and Hawkins, 2010). The third case can be considered as 
initiated but unfinished apoptosis. The changes in XIAP levels disturb the normal 
control of the switch, which controls the activation of effector caspases and disrupts the 
normal relationships between the activation of effector caspases and the cell death 
(Spencer and Sorger, 2011). The numerical simulations performed using our model 
with the HeLa experimental parameters are consistent with the above ideas. 
At individual cell level, apoptosis exhibits variability in timing, even amongst the cells 
of the same population. Single cell experiments show, that some cells die within the 45 
minutes after the exposition to cell death signal, while others survive 12 or more hours 
(Spencer and Sorger, 2011). Individual mitochondria within the same cell differ in their 
sensitivity  to  proapoptotic  stimuli  and  MOMP  may  not  fit  “all  or  nothing”  picture  for  
all cells (Tait et al., 2010). The MOMP activation thresholds do differ between the 
cells, reflecting most probably the physiological variations of the Bcl–2 protein family 
accomplishing the Bcl–2 switch. The computational model presented here allows for 
variations in individual cell behavior due to variations in internal states and the 
intensity (Fig. 3) and duration of proapoptotic stimuli. Numerical simulations suggest 
expected preservation of switching behavior. Lower levels of death stimuli lead to 
slower Bid truncation and the slower onset of apoptosis. In the case of 
receptor-mediated apoptosis, MOMP is preceded by a time interval, duration of which 
is dependent on the dose of stimulus, while the MOMP transition time and post-MOMP 
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course of events are practically dose-independent. 
The variability of timing and the probability of apoptosis itself reflects the differences 
between the cells at genetic and epigenomic levels, different phase of cell cycle, 
stochastic fluctuations of biochemical reactions and natural variations in protein 
concentrations. Variations in mRNA levels are reflected in variations of the speed of 
proteosynthesis. Short-living proteins, or proteins with low number of copies per cell 
are more vulnerable to such fluctuations, while for more abundant proteins, e.g. part of 
those controlling apoptosis, the most significant cause is the variability of individual 
static cell proteome. The explorations of the cell variabilities and their properties 
encoded in the model will be subject of our future work. 
Conclusion 
Predictive modeling of apoptosis, using multifactor, context-sensitive and quantitative 
data provides the opportunity to distinguish specific responses of individual cell lines 
and cells to the uniform treatment. Improved and finely tuned models may one day 
form the base for rational design of individual treatment, tailored toward the medicinal 
applications. The computational model of TNF signaling pathway seems to provide 
encouraging results. On the other hand, the amount of specific reliable experimental 
data needs to grow as well to provide higher level of confidence and improve the 
predictive power of the models. 
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Figure legends 
Fig.1. Conceptual scheme of the TNF signaling model. 
The individual modules of the reaction network are differentiated through different 
background. The boundaries between reaction compartments (extracellular space, 
cytoplasm, nucleus and mitochondria) are marked with lines. Stimulation of the 
TNF-R1 receptor by TNF-α (TNF) ligand leads to the formation of signaling 
complexes I (SC1) and II (SC2),  which  are  activating  antiapoptotic  NFĸB  and  apoptotic 
signaling pathways. Further antiapoptotic proteins Bcl2_c (cytosolic Bcl–2), Bcl2_m 
(mitochondrial Bcl–2) and BAR are denoted by gray background. Extracellular space, 
cytoplasm, nucleus and mitochondria form separate compartments with associated 
reactions. Mitochondria is marked as an open space, leaking CytC (cytochrome-c) and 
Smac into surrounding cytosol, due to formation of permeable pores (M#). In the 
scheme, the symbol ⊥ denotes an inhibition, while the arrows stand for reactions, 
activations, transformations and transport between the compartments. To reduce visual 
clutter, shortened forms of names are used when appropriate (C3 stands for caspase–3, 
pC9 for procaspase–9, Bcl2_c for cytosolic Bcl2, Bcl2_m for mitochondrial Bcl2 
(Bcl-xL)). Full names of the species are specified in the Table 3. 
Fig. 2. Simulated time course of the selected molecular concentrations after the 
application of apoptotic stimulus of 3000 molecules of TNF per HeLa cell. The 
concentration of antiapoptotic XIAP rises due to activation of antiapoptotic NFĸB 
pathway. After two hours the mitochondrial membrane is permeabilized and apoptotic 
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proteins (Smac) are released. The drop of XIAP due to interaction of Smac with XIAP 
is compensated by further synthesis of XIAP (around 10000 seconds from the 
beginning). After the cytochrome-c is released, apoptosome is formed, and caspase–8 
activates very effective caspase–3 (C3). Caspase–3 cleaves the XIAP as well as PARP 
substrate. The time, when the PARP to cleaved cPARP ratio is 1:1 is sometimes 
referred as the beginning of apoptosis (here at about 15000 seconds). 
Fig. 3. Time dependence of some critical components of apoptotic mechanism - 
dependence on size of input stimuli. TNF stimulus varies from 120 to 6000 molecules 
per cell. XIAP concentrations are scaled down by factor 10 (XIAP_norm = 
[XIAP(t)]/10) to fit on the same figure. Lower levels of input stimuli lead to higher 
synthesis of XIAP and delayed activity of caspase–3. 
Fig. 4. Time course of the molecular concentrations after exposing cells to TNF 
stimulus. For selected molecular species, the time course is depicted on the figure. On 
top, the simulations are made with the presented model and the initial amounts 
corresponding directly to the experimental data taken from proteomics experiment on 
HeLa cells. On bottom, the same simulation using the KYM1 specific cell line 
parameters for RIP1, TRADD and TRAF2. Low initial concentrations of these adaptor 
proteins for HeLa cells cause different activation pattern of FLIP, XIAP and caspase–8. 
On x-axis the time is specified in seconds, on y-axis amounts of molecular species per 
reference cell. In order to fit the selected molecules into the same frame, more abundant 
proteins were scaled down (scaling indicated by _norm suffix). Meaning of the 
symbols: SC1 and SC2: signaling complexes I and II, respectively. FLIP_norm = 
[FLIP(t)]/600, XIAP_norm = [XIAP(t)]/125000, C8_norm = [C8(t)]/125000, 
NFkB_norm =[NFkB(t)]/30 
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Fig. 5. Why the rise of active caspase–3 concentration is delayed 6000 s after the 
MOMP event? 
Time course of the events after the stimulus 3000 molecules of TNF is applied. Even 
before MOMP (at 9000 s) we may observe small amount of active caspase–3 (C3_tot 
comprised of C3:pC6+C3+XIAP:C3) in cytosol. The activity of caspase–3 (C3) is 
blocked by excessive XIAP before MOMP completely and after the MOMP partially. 
After MOMP, the amount of XIAP is decreased by two mechanisms: inhibition by 
(MOMP released) Smac and apoptosome (formed after some delay using MOMP 
released cytochrome-c) and increased C3 production (C3:XIAP). Finally, the activity 
of caspase–3 (C3) is notably rised - as evidenced by both absolute count of caspase–3 
(C3) and its share on total number of C3_tot. Due to high dynamical range of molecular 
concentrations, the variables has been scaled to fit the same figure as follows: 
CytCr_norm  =  [“cytochrome-C  released”(t)]/6,  C3_tot_norm  =  
([C3:pC6(t)]+[C3(t)]+[XIAP:C3(t)])/1100), C3_norm = [C3(t)]/700, XIAP:C3_norm 
= [XIAP(t)|]/1000, XIAP_tot_norm = 
([XIAP(t)]+[Apop:XIAP(t)]+[Smac:XIAP(t)]+[XIAP:C3(t)])/5000, 
Smac:XIAP_norm=[Smac:XIAP(t)]/1000 
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Table 1. List of main reactions in the model 
 Reaction1 Kinetic 
parameter 
Compartment volume 
factor2 
1 TNFR → TNFR_E k1   
2 TNFR_E + TNF_E ⇌TNF:TNFR_E k2 k_2  
3 TNF:TNFR_E + TRADD → TNF:TNFR:TRADD k3   
4 RIP + TRAF2 + TNF:TNFR:TRADD → SC1 k4   
5 IKK → IKKa;  SC1 k5   
6 IKKa → IKK k6   
7 SC1 → TRAF2 + TNF:TNFR:TRADD;  A20 k7   
8 NFkB + IkBa → IkBa:NFkB k8   
9 IkBa:NFkB → NFkB + PIkBa;  IKKa k9   
10 NFkB → NFkB_N k10   
11 → IkBa_mRNA;  NFkB_N k11  VNC 
12 → IkBa;  IkBa_mRNA k12   
13 IkBa ⇌IkBa_N k13 k_13  
14 NFkB_N + IkBa_N → IkBa:NFkB_N k14  VNC 
15 IkBa:NFkB_N → IkBa:NFkB k15   
16 → A20_mRNA;  NFkB_N k16  VNC 
17 → A20;  A20_mRNA k17   
18 → XIAP_mRNA;  NFkB_N k18  VNC 
19 → XIAP;  XIAP_mRNA k19   
20 → FLIP_mRNA;  NFkB_N k20  VNC 
21 → FLIP;  FLIP_mRNA k21   
22 SC1 → Cint1 k22   
23 Cint1 → RIP + TRAF2 + Cint2 k23   
"""""""""""""""""""""""""""""" """""""""""""""""""""""""""""
1"The molecular species appearing in reactions are characterized in Table 3. Remaining synthesis and 
degradation reactions (not listed for brevity) are for all species in the form   
Null ⇌  Species   
with synthesis rate ks and degradation rate kdeg specified in Table 3.  
 
2"When listed, VNC (volume of nuclei to cytosol) and VMC (volume of mitochondria to cytosol) 
correction factors are applied for reaction rates to account for increased speed of reactions in  smaller 
reaction volumes (Albeck et al., 2008). 
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24 2 * FADD + Cint2 → Cint3 k24   
25 Cint3 → SC2 k25   
26 SC2 + FLIP → SC2:FL k26   
27 FLIP + SC2:FL → SC2:FL:FL k27   
28 SC2 + pC8 → SC2:pC8 k28   
29 SC2:pC8 + pC8 → SC2:pC8:pC8 k29   
30 SC2:pC8:pC8 → SC2 + C8 k30   
31 FLIP + SC2:pC8 → SC2:FL:pC8 k31   
32 SC2:FL + pC8 → SC2:FL:pC8 k32   
33 SC2:FL:pC8 → SC2 + C8 k33   
34 RIP + TRAF2 + SC2:FL:pC8 → 
SC2:FL:pC8:RIP:TRAF2 
k34   
35 IKK → IKKa;  SC2:FL:pC8:RIP:TRAF2 k35   
36 BAR + C8 ⇌BAR:C8 k36 k_36  
37 pC3 + C8 ⇌C8:pC3 k37 k_37  
38 C8:pC3 → C8 + C3 k38   
39 C3 + pC6 ⇌C3:pC6 k39 k_39  
40 C3:pC6 → C3 + C6 k40   
41 C6 + pC8 ⇌C6:pC8 k41 k_41  
42 C6:pC8 → C8 + C6 k42   
43 XIAP + C3 ⇌XIAP:C3 k43 k_43  
44 XIAP:C3 → XIAP k44   
45 RIP → ;  C3 k45   
46 FLIP → ;  C3 k46   
47 PARP → cPARP;  C3 k47   
48 C8 + Bid ⇌C8:Bid k48 k_48  
49 C8:Bid → tBid + C8 k49   
50 tBid + "cytosolic Bcl-2" ⇌Bcl2c:tBid k50 k_50  
51 tBid + Bax ⇌Bax:tBid k51 k_51  
52 Bax:tBid → tBid + Bax# k52   
53 Bax# ⇌Baxm k53 k_53  
54 Baxm + Bcl-2 ⇌Baxm:Bcl2 k54 k_54 VMC 
55 2 * Baxm ⇌Bax2 k55 k_55 VMC 
4"
"
56 2 * Bax2 ⇌Bax4 k56 k_56 VMC 
57 Bcl-2 + Bax2 ⇌Bax2:Bcl2 k57 k_57 VMC 
58 Bcl-2 + Bax4 ⇌Bax4:Bcl2 k58 k_58 VMC 
59 Bax4 + M ⇌Bax4: k59 k_59 VMC 
60 Bax4:M → M# k60   
61 M# + CytoC_m ⇌M#:CytoC_m k61 k_61 VMC 
62 M#:CytoC_m → "CytoC released" + M# k62   
63 M# + Smac_m ⇌M#:Smac_m k63 k_63 VMC 
64 M#:Smac_m → M# + "Smac released" k64   
65 "CytoC released" ⇌CytoC k65 k_65  
66 CytoC + Apaf ⇌CytoC:Apaf k66 k_66  
67 CytoC:Apaf → CytoC + Apaf# k67   
68 Apaf# + pC9 ⇌Apop k68 k_68  
69 pC3 + Apop ⇌pC3:Apop k69 k_69  
70 pC3:Apop → C3 + Apop k70   
71 "Smac released" ⇌Smac k71 k_71  
72 XIAP + Apop ⇌Apop:XIAP k72 k_72  
73 XIAP + Smac ⇌ Smac:XIAP k73 k_73  
74 M# → M k74   
75 XIAP →; C3 k75   
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Table 2. Kinetic rate parameters 
Name Value Units3 Source4 
k1 0.001 s-1 (Schl) 
k2 1.6e-08 s-1*(#/ CC)-1   (Schl) 
 k_2 6.60377e-05 s-1 (Schl) 
k3 7e-09 s-1*(#/ CC)-1   (Schl) 
k4 2.693e-13     s-1*(#/ CC)-2 (Schl) 
k5 0.0001555668 s-1*(#/ CC)-1   (Schl) 
k6 0.1 s-1 (Schl) 
k7 1e-08 s-1*(#/ CC)-1   (Schl) 
k8 2.076e-06 s-1*(#/ CC)-1   (Schl) 
k9 1.73e-07 s-1*(#/ CC)-1   (Schl) 
k10 0.0125 s-1 (Schl) 
k11 3.0303e-05 s-1 (Schl) 
k12 0.0606061 s-1 (Schl) 
k13 0.0151515 s-1 (Schl) 
    k_13 0.00257576 s-1 (Schl) 
k14 2.383e-06 s-1*(#/ CC)-1   (Schl) 
k15 0.0151515 s-1 (Schl) 
k16 3.78788e-05 s-1 (Schl) 
k17 0.0151515 s-1 (Schl) 
k18 3.33333e-05 s-1 (Schl) 
k19 0.0506061 s-1 (Schl) 
k20 3.33333e-05 s-1 (Schl) 
k21 0.00687273 s-1 (Schl) 
k22 0.001135 s-1 (Schl) 
k23 0.001135 s-1 (Schl) 
k24 3.27e-14      s-1*(#/ CC)-2 (Schl) 
k25 0.1135 s-1 (Schl) 
k26 5.19e-07 s-1*(#/ CC)-1   (Schl) 
k27 5.19e-07 s-1*(#/ CC)-1   (Schl) 
k28 5.19e-08 s-1*(#/ CC)-1   (Schl) 
k29 5.19e-08 s-1*(#/ CC)-1   (Schl) 
k30 0.45 s-1 (Schl) 
"""""""""""""""""""""""""""""" """""""""""""""""""""""""""""
3"#/CC"*""number"of"copies"of"molecule"per"cell"cytosolic"volume 
4"Alb"–"(Albeck"et"al.,"2008),"Aldr"–"(Aldridge"et"al.,"2011),"Schl"–"(Schliemann"et"al.,"2011),"Spen"–"(Spencer"and"
Sorger,"2011) 
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k31 5.19e-07 s-1*(#/ CC)-1   (Schl) 
k32 5.19e-07 s-1*(#/ CC)-1   (Schl) 
k33 0.3 s-1 (Schl) 
k34 2.7e-14     s-1*(#/ CC)-2 (Schl) 
k35 5.2e-08 s-1*(#/ CC)-1   (Schl) 
k36 8.65e-07 s-1*(#/ CC)-1   (Schl) 
     k_36 0.001 s-1 (Schl) 
k37 1e-07 s-1*(#/ CC)-1   (Alb) 
     k_37 0.001 s-1 (Alb) 
k38 1 s-1 (Alb) 
k39 1e-07 s-1*(#/ CC)-1   (Spen) 
     k_39 0.001 s-1 (Alb) 
k40 1 s-1 (Alb) 
k41 1e-07 s-1*(#/ CC)-1   (Spen) 
     k_41 0.001 s-1 (Alb) 
k42 1 s-1 (Alb) 
k43 1.038e-06 s-1*(#/ CC)-1   (Alb) 
     k_43 0.001 s-1 (Alb) 
k44 5e-05 s-1 (Alb) 
k45 2.59e-07 s-1*(#/ CC)-1   (Alb) 
k46 2.59e-07 s-1*(#/ CC)-1   (Alb) 
k47 3.11e-07 s-1*(#/ CC)-1   (Alb) 
k48 1e-07 s-1*(#/ CC)-1   (Alb) 
     k_48 0.001 s-1 (Alb) 
k49 1 s-1 (Alb) 
k50 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_50 0.001 s-1 (Alb) 
k51 1e-07 s-1*(#/ CC)-1   (Alb) 
     k_51 0.001 s-1 (Alb) 
k52 1 s-1 (Alb) 
k53 0.01 s-1 (Alb) 
     k_53 1 s-1 (Spen)  
k54 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_54 0.001 s-1 (Alb) 
k55 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_55 0.001 s-1 (Alb) 
k56 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_56 0.001 s-1 (Alb) 
k57 1e-06 s-1*(#/ CC)-1   (Alb) 
7"
"
     k_57 0.001 s-1 (Alb) 
k58 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_58 0.001 s-1 (Alb) 
k59 1e-06 s-1*(#/ CC)-1   (Alb) 
     k_59 0.001 s-1 (Alb) 
k60 1 s-1 (Alb) 
k61 2e-06 s-1*(#/ CC)-1   (Alb) 
     k_61 0.001 s-1 (Alb) 
k62 10 s-1 (Alb) 
k63 2e-06 s-1*(#/ CC)-1   (Alb) 
     k_63 0.001 s-1 (Alb) 
k64 10 s-1 (Alb) 
k65 1 s-1 (Spen) 
     k_65 0.01 s-1 (Alb) 
k66 5e-07 s-1*(#/ CC)-1   (Alb) 
     k_66 0.001 s-1 (Alb) 
k67 1 s-1 (Alb) 
k68 5e-08 s-1*(#/ CC)-1   (Alb) 
     k_68 0.001 s-1 (Alb) 
k69 5e-09 s-1*(#/ CC)-1   (Alb) 
     k_69 0.001 s-1 (Alb) 
k70 1 s-1 (Alb) 
k71 1 s-1 (Spen) 
     k_71 0.01 s-1 (Alb) 
k72 2e-06 s-1*(#/ CC)-1   (Alb) 
     k_72 0.001 s-1 (Alb) 
k73 7e-06 s-1*(#/ CC)-1   (Alb) 
    k_73 0.001 s-1 (Alb) 
k74 0.0001 s-1 (Aldr) 
k75 3.114 s-1*(#/ CC)-1   (Schl) 
VNC 0,25   
VMC 0,1   
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Table 3. Initial conditions, synthesis and degradation rates 
Symbol #/CC     
source:
MS 
ks 
(#* s-1) 
kdeg 
(s-1) 
Source 
of 
reaction 
rates5 
Notes Com
part
ment
6 
TNFR  168 0.168  (Schl) Newly synthetized TNF 
receptor 
CC 
RIP  9500  12 0.0001 (Schl) Receptor-interacting 
protein (RIPK1) 
CC 
TRADD  50000  17.7 0.0001 (Schl) TNFR1-associated 
DEATH domain protein 
(TRADD) 
CC 
TRAF2  13000 19.9 0.0001 (Schl) TNF receptor-associated 
factor 2 (TRAF2) 
CC 
FADD  18000 0 18.6 0.0001 (Schl) FAS-associated death 
domain protein (FADD) 
CC 
TNF:TNFR:TRADD  0   0.02352 (Schl) TNF~TNFR~TRADD 
complex  
CC 
SC1  0   5.6e-05 (Schl) TNF-R1-complex 
containing RIP and 
TRAF2 (signaling 
complex I) 
CC 
Cint1  0     internalized signaling 
complex I, state 1 
CC 
Cint2  0     internalized signaling 
complex I, state 2 
CC 
Cint3  0     internalized signaling 
complex I, state 3 
CC 
SC2  0   5.6e-05 (Schl) TNF-R1-complex 
containing FADD 
(signaling complex II) 
CC 
FLIP  0 1.354348 0.0001 (Schl) FLICE-inhibitory 
protein (CFLAR) 
CC 
SC2:FL  0   5.6e-05 (Schl) SC2~FLIP complex CC 
SC2:pC8  0   5.6e-05 (Schl) SC2~procaspase-8 
complex 
CC 
SC2:FL:FL  0   5.6e-05 (Schl) SC2~FLIP~FLIP 
complex 
CC 
SC2:pC8:pC8  0   5.6e-05 (Schl) SC2~procaspase-
8~procaspase-8 complex 
CC 
SC2:FL:pC8  0   5.6e-05 (Schl) SC2~FLIP~procaspase-
8 complex 
CC 
"""""""""""""""""""""""""""""" """""""""""""""""""""""""""""
5"Alb"–"(Albeck"et"al.,"2008),"Aldr"–"(Aldridge"et"al.,"2011),"Schl"–"(Schliemann"et"al.,"2011),"Spen"–"(Spencer"and"
Sorger,"2011) 
 
6"compartments:"CC"–"cytosol,"MC"–"mitochondria,"NC"–"nucleus,"EC*"extracelular"space."The"size"of"EC"was"set"
to"equal"CC. 
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SC2:FL:pC8:RIP:TRA
F2  
0   5.6e-05 (Schl) SC2~p43-FLIP  
complex with RIP 
and TRAF2  
CC 
IKK  3500  38.541 0.0001 (Schl) Inhibitor-kB kinase, 
inactive form 
[IKK1 (CHUK), IKK2 
(IKBKB), NEMO 
(IKBKG)] 
CC 
IKKa  0   0.0001 (Schl) active form IKK CC 
A20  1600  5.78 0.0001 (Schl) Tumor necrosis factor, 
alpha-induced protein 3 
(TNFAIP3) 
CC 
NFkB  75 0.96352 0.0001 (Schl) Nuclear factor κB [p50 
(NFKB1), p65 (RELA)] 
CC 
IkBa  67060  0.00154022 (Schl) Inhibitor-κBα 
(NFKBIA) 
CC 
IkBa:NFkB  5840  0.0001 (Schl) IκBα ~NF-κB complex CC 
PIkBa  0   0.0115517 (Schl) Phosphorylated  form of 
IκBα 
CC 
BAR  0 1 5.78704e-05 (Schl) Bifunctional apoptosis 
regulator (BFAR) 
CC 
XIAP  27000  465 0.0001 (Schl) X-linked inhibitor of 
apoptosis protein 
(XIAP) 
CC 
pC8  70000  118.9531
682 
6.17284e-05 (Schl) procaspase-8 (CASP8) CC 
pC3  64000 29.73826
2 
6.17284e-05 (Schl) procaspase-3 (CASP3) CC 
pC6  12000  2.379 6.17284e-05 (Schl) procaspase-6 (CASP6) CC 
C8  0   5.78704e-05 (Schl) caspase-8 CC 
C3  0   5.78704e-05 (Schl) caspase-3 CC 
C6  0   5.78704e-05 (Schl) caspase-6 CC 
BAR:C8  0   5.78704e-05 (Schl) BAR~caspase-8 
complex 
CC 
XIAP:C3  0   5.78704e-05 (Schl) XIAP~caspase-3 
complex 
CC 
PARP  400000  5.808 5.78704e-06 (Schl) Poly [ADP-ribose] 
polymerase1 (PARP1) 
320000#, lumped PARP 
species   
CC 
cPARP  0   5.78704e-06 (Schl) Cleaved PARP CC 
C6:pC8  0   2.9e-06 (Spen) Caspase-6~procaspase-8 
complex 
CC 
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C8:pC3  0   2.9e-06 (Spen) Caspase-8~procaspase-3 
complex 
CC 
Bid  440000  0.02610 2.9e-06 (Spen) BH3 interacting domain 
death agonist (BID) 
CC 
C8:Bid  0   2.9e-06 (Spen) Caspase-8~Bid komplex CC 
tBid  0   2.9e-06 (Spen) truncated Bid CC 
Apop  0   2.9e-06 (Spen) apoptosome  CC 
pC3:Apop  0   2.9e-06 (Spen) procaspase-
3~apoptosome complex 
CC 
C3:pC6  0   2.9e-06 (Spen) Caspase-3~procaspase-6 
complex 
CC 
Apop:XIAP  0   2.9e-06 (Spen) Apoptosome~XIAP 
complex 
CC 
Smac  0   2.9e-06 (Spen) cytosolic Smac CC 
Smac:XIAP  0   2.9e-06 (Spen) Smac~XIAP complex CC 
"cytosolic Bcl-2"  25000 0.00870 0.0001 (Spen) B-cell CLL/lymphoma 2 
(BCL2) 
CC 
Bax  500000  0.03480 2.9e-06 (Spen) BCL2-associated X 
protein (BAX) 
CC 
Bax:tBid  0   2.9e-06 (Spen) Bax~tBid complex CC 
Bax#  0   2.9e-06 (Spen) active form Bax CC 
CytoC  0   2.9e-06 (Spen) cytochromee c  CC 
Apaf  3300  0.04350 2.9e-06 (Spen) Apoptotic peptidase 
activating factor1 
(APAF1) 
CC 
CytoC:Apaf  0   2.9e-06 (Spen) CytoC~Apaf complex CC 
Apaf#  0   2.9e-06 (Spen) active form Apaf CC 
pC9  6500  0.04350 2.9e-06 (Spen) Procaspase-9 (CASP9) CC 
Bcl2c:tBid  0   2.9e-06 (Spen) Bcl2~tBid complex CC 
TNFR_E  2850  5.6e-05 (Schl) TNFR1 dimer 
(TNFRSF1A), 
(TNFRSF1B), both are 
missing in MS data  
EC 
TNF_E  3000  2.9e-06 (Schl)  stimulus  Tumor 
Necrosis Factor (TNF) 
EC 
TNF:TNFR_E  0   5.6e-05 (Schl) ligand~receptor complex EC 
NFkB_N  251  0.0001 (Schl) nuclear NF-κB NC 
IkBa_N  16766  0.0001 (Schl) nuclear IκBα NC 
IkBa:NFkB_N  334  0.0001 (Schl) IκBα ~NF-κB complex 
in nucleus 
NC 
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A20_mRNA  34  0.000470498 (Schl) A20-encoding  mRNA  NC 
IkBa_mRNA  32  0.000394201 (Schl) IκBα-encoding  mRNA NC 
XIAP_mRNA  132  0.000104931 (Schl) XIAP-encoding mRNA NC 
FLIP_mRNA  84  0.000165744 (Schl) FLIP-encoding mRNA NC 
Bax2  0   2.9e-06 (Spen) Bax dimer  MC 
Bax2:Bcl2  0   2.9e-06 (Spen) Bax2~Bcl2 complex  MC 
Bax4  0   2.9e-06 (Spen) Bax tetramer MC 
Bax4:Bcl2  0   2.9e-06 (Spen) Bax4~Bcl2 complex MC 
Bax4:M  0   2.9e-06 (Spen) Bax4~pore komplex MC 
Baxm  0   2.9e-06 (Spen) Bax in mitochondria MC 
Baxm:Bcl2  0   2.9e-06 (Spen) Baxm~Bcl2 complex MC 
Bcl-2  60000  0.00870 2.9e-06 (Spen) BCL2-like 1 (BCL2L1) MC 
"CytoC released"  0   2.9e-06 (Spen) cytochrome c released 
but remaining in the MC 
MC 
CytoC_m  160000  0.21750 2.9e-06 (Spen) cytochrome c (CYCS) MC 
M  720000  0.21750 2.9e-06 (Spen) Translocator protein 
pore (TSPO) 
MC 
M#  0     Activated  pore MC 
M#:Smac_m  0   2.9e-06 (Spen) pore~Smac_m complex MC 
"Smac released"  0   2.9e-06 (Spen) Smac released but 
remaining in the MC 
MC 
M#:CytoC_m  0   2.9e-06 (Spen) M#~CytoC_m complex MC 
Smac_m  270000 0.04350 2.9e-06 (Spen) IAP-binding 
mitochondrial protein 
(DIABLO) 
MC 
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Table 4. Initial concentration of selected species in three different models 
Molecule Mass Spectrometry, 
HeLa, #/cell 
Schliemann, KYM1, 
#/cell 
Spencer, HeLa, #/cell 
RIP 9500 121985  
TRADD 50000 176714  
TRAF2 13000 199068  
FLIP 0 19299 2000 
IKK 3500 385417  
A20 1600 62891  
BAR 0 173371 1000 
XIAP 27000 4717570 100000 
pC8 70000 1927090 10000 
pC3 64000 481771 10000 
pC6 12000 38542 10000 
IkBa (total) 90000 7253  
NFkB (total) 6500 5621  
BID 440000  60000 
BAX 500000  80000 
CytoC_m 160000  500000 
Smac_m 270000  100000 
Apaf 3300  100000 
pC9 6500  100000 
"
